E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
(very early) systemic sclerosis |
|
E.1.1.1 | Medical condition in easily understood language |
systemic sclerosis / scleroderma |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the changes of high dose intravenous methylprednisolone on nail fold capillaries as measured by nail fold capillary microscopy (NCM) at week 12 |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effects of glucocorticoids on signs and symptoms of disease progression.
To analyze the effect of glucocorticoids on inflammatory biomarkers that have been implicated in SSc pathogenesis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age ≥ 18 years
- Fulfilling VEDOSS criteria:
• Raynauds’ Phenomenon and
• Positive for disease specific auto antibodies (anti-centromere or anti-topoisomerase antibodies) and
• Systemic sclerosis specific nail fold capillaroscopic findings
- Puffy fingers < 3 years duration
- modified Rodnan Skin Score =0
- Written informed consent
|
|
E.4 | Principal exclusion criteria |
- Presence of acrosclerosis, acrosteolysis and digital ulcers
- Presence of anti-RNA polymerase III auto antibodies
- Previous systemic treatment for SSc, namely methotrexate, prednisone (> 14 days in previous 6 months), mofetyl mycophenolate and cyclophosphamide.
- Clinically significant internal organ involvement: DLCO< 80% predicted, VC < 70% predicted, renal dysfunction with GFR < 60 ml/min, diastolic dysfunction > grade 1 on echocardiography, pulmonary hypertension, weight loss >10% in the last 6 months with unknown cause.
- Contra-indications for methylprednisolone, such as pregnancy, lactation, psychotic or depressive disorder, ulcus duodeni or ventriculi, untreated hypertension (> 160-90 mmHg) or acute infections.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
In this study, the primary endpoint will be the change in capillary density between baseline and 12 weeks. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes of this study are: (all compared between baseline and week 12 and between baseline and 1 year) change in selected biomarkers: the interferon signature in peripheral blood cells CXCL4, IL-1β, IL-6, TNF-α, ET-1, ICAM-1 and VEGF; change in nail fold capillary changes other than capillary density and giant capillaries; changes in nail fold capillary pattern (early, active, late, normal); change in modified Rodnan skin score; presence of puffy fingers; presence of synovitis, presence of tendon friction rubs; fulfilling EULAR/ACR classification criteria for SSc (24), pulmonary function tests; presence of interstitial lung disease; suspicion of PH; and physical function, general health and utilities as measured by the SHAQ, SF-36, EQ5D and GIT. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |